Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.65 USD | -6.33% | +7.25% | +5.86% |
Financials (USD)
Sales 2024 * | 80.45M | Sales 2025 * | 38.54M | Capitalization | 1.45B |
---|---|---|---|---|---|
Net income 2024 * | -485M | Net income 2025 * | -579M | EV / Sales 2024 * | 9.33 x |
Net cash position 2024 * | 698M | Net cash position 2025 * | 766M | EV / Sales 2025 * | 17.7 x |
P/E ratio 2024 * |
-2.99
x | P/E ratio 2025 * |
-2.7
x | Employees | 587 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.3% |
Latest transcript on Vir Biotechnology, Inc.
1 day | -6.33% | ||
1 week | +7.25% | ||
Current month | +25.89% | ||
1 month | +31.00% | ||
3 months | -7.63% | ||
6 months | +8.23% | ||
Current year | +5.86% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 55 | - | |
Sung Lee
DFI | Director of Finance/CFO | 53 | 23-03-26 |
Jennifer Towne
CTO | Chief Tech/Sci/R&D Officer | - | Nov. 05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Charles Sigal
BRD | Director/Board Member | 72 | 20-07-01 |
Robert Perez
BRD | Director/Board Member | 59 | 16-12-31 |
Robert More
BRD | Director/Board Member | 56 | 16-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
12.90% | 254 M€ | +12.80% | - | |
0.63% | 28 M€ | -2.47% | ||
0.58% | 25 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 10.65 | -6.33% | 906,720 |
24-05-22 | 11.37 | +11.36% | 1,629,897 |
24-05-21 | 10.21 | +5.37% | 883,057 |
24-05-20 | 9.69 | -0.41% | 567,223 |
24-05-17 | 9.73 | -2.01% | 644,741 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.86% | 1.55B | |
+64.92% | 62.59B | |
-1.85% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.05% | 26.21B | |
-21.96% | 19.09B | |
+4.21% | 13.08B | |
+25.74% | 12.26B | |
+27.42% | 12.05B |
- Stock Market
- Equities
- VIR Stock